TRXC 通過 FDA 了 - 股票

※ 引述《Severine (賽非茵)》之銘言：
: 原文標題：
這隻我不但有繼續留著 都沒賣

3.7 我又加倉的原始倉位的30%

等於是我現在有N萬股 成本在1.7

牛排加大在加大

全熟牛排加番茄醬最好吃



聽說前幾天有人對我的to the moon

有意見

什麼古板壞人多

剛好那篇文章一發就是最低點

我有在裡面推文說買進訊號來了

有上車的朋友恭喜了


今年牛排加大在加大

那些平常只做台股的

不要隨便做美股啦

你們英文不好閱讀速度又慢

上上下下的你們根本看不懂

先去地球村補美語再來跟我做美股啦
: Asensus Surgical (TRXC) Announces FDA Clearance in General Surgery
: 原文連結：https://bit.ly/3q9VDlV
: 發布時間：March 3, 2021 6:55 AM EST
: 原文內容：
: Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) ,
: a medical device company that is digitizing the interface between the surgeon
: and patient to pioneer a new era of Performance-Guided Surgery™, today
: announced the Company has received an additional FDA clearance for the
: Senhance Surgical System which allows for indication expansion in general
: surgery in the United States.
: Asensus Surgical's technology platform, Senhance® Surgical System, is the
: first of its kind digital laparoscopic platform that leverages augmented
: intelligence to provide unmatched performance and patient outcomes through
: machine learning. Senhance goes beyond the typical surgical robotic systems,
: providing surgical assurance through haptic feedback, eye-tracking camera
: control, and 3D visualization, and is the first platform to offer 3 mm
: instruments (the smallest instrument available in the world on a robotic
: surgical platform).
: “The expansion into general surgery for the Senhance Surgical System is a
: major milestone for the growth and clinical applicability of our technology,”
: said Anthony Fernando, Asensus Surgical President and CEO. “General surgery
: is, by far, the largest area of manual laparoscopy which can benefit from the
: precision and insight of Performance-Guided Surgery. The indication expansion
: allows Senhance to be used in many high-value, complex reconstructive
: surgeries such as those used to treat reflux and obesity. Including previous
: indications granted, the Senhance Surgical System can now be utilized in over
: 2.7 million general surgical procedures performed in the US annually."
: “Many of the procedures we perform in general surgery require complex
: reconstruction throughout a wide surgical field,” said Dr. Sabino Zani,
: Assistant Professor of Surgery at Duke University and an investigator in the
: clinical studies submitted for indication expansion. “Senhance can now be
: seen as a widely applicable tool for general surgeons across the broad range
: of procedures that may be performed from deep in the pelvis to the upper
: abdomen.”
: Senhance US Indication for Use
: The Senhance Surgical System is intended to assist in the accurate control of
: laparoscopic instruments for visualization and endoscopic manipulation of
: tissue including grasping, cutting, blunt and sharp dissection,
: approximation, ligation, electrocautery, suturing, mobilization, and
: retraction. The Senhance Surgical System is intended for use in general
: laparoscopic surgical procedures and laparoscopic gynecological surgery. The
: system is indicated for adult use. It is intended for use by trained
: physicians in an operating room environment in accordance with the
: instructions for use.
: 心得/評論： ※必需填寫滿20字
: 前陣子的飆股,雖然二月有滿滿的預期會通過FDA 但大漲大跌之下還是賣了一點
: 部位.這陣子的回調原本希望回到3.5再加倉,這下看來沒機會了..
: ----------------------------------發文提醒-------------------------------
: 1.發文前請先詳閱[新聞]分類發文規範，未依規範發文將受處份。
: 2.連結過長請善用 https://bit.ly/ 縮網址，連結能不能點擊者板規1-2-2處份。
: 3.心得/評論請盡量充實，*[m心得過短或濫竽充數將會以1-2-3&一行文規範水桶處份
: 4.發文請依照格式文章標明段落，不符合格式者依4-1刪文處分。
: ------------------ 以上注意事項請勿刪除 違者4-1 刪文處分-----------------

-----
Sent from JPTT on my iPhone

--